These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1593 related articles for article (PubMed ID: 33753110)

  • 1. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
    Shi SL; Zhang ZH
    Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.
    Li X; Zheng H
    Thorac Cancer; 2020 Feb; 11(2):295-304. PubMed ID: 31788970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding HOXA11-AS knockdown suppresses the progression of non-small cell lung cancer by regulating miR-3619-5p/SALL4 axis.
    Xia H; Niu Q; Ding Y; Zhang Z; Yuan J; Jin W
    J Mol Histol; 2021 Aug; 52(4):729-740. PubMed ID: 34050851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.
    Pang L; Cheng Y; Zou S; Song J
    Thorac Cancer; 2020 Feb; 11(2):264-276. PubMed ID: 31793741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer.
    Chang F; Li J; Sun Q; Wei S; Song Y
    Bioengineered; 2022 Apr; 13(4):8806-8822. PubMed ID: 35287543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA SNHG1 promotes non-small cell lung cancer progression by up-regulating MTDH via sponging miR-145-5p.
    Lu Q; Shan S; Li Y; Zhu D; Jin W; Ren T
    FASEB J; 2018 Jul; 32(7):3957-3967. PubMed ID: 29466052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer.
    Wu C; Hu Y; Ning Y; Zhao A; Zhang G; Yan L
    Cancer Biother Radiopharm; 2020 Dec; 35(10):741-752. PubMed ID: 32407172
    [No Abstract]   [Full Text] [Related]  

  • 15. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
    Yu L; Chen D; Song J
    Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
    Tan D; Wang S; Zhang P; Peng C; Wu T
    Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.